Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863519 | 0.78 | KDM4E (0.42) | KDM4ESMN1; SMN2ERN1 | |
| SCHEMBL217044 | 0.72 | MAPT (1.00) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL28420480 | 0.70 | MAPT (0.94) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL1498128 | 0.69 | MAPT (0.58) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL83269 | 0.68 | — | — | |
| SCHEMBL2926836 | 0.68 | MAPT (0.89) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL29539091 | 0.68 | MAPT (0.89) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL29852620 | 0.67 | MAPT (0.54) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL2087722 | 0.67 | MAPT (0.54) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL5026012 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
| US-6150379-A | BLOOD COAGULATION FACTOR XA INHIBITORS; TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE ACTIVITY; THROMBOLYTIC AND ISCHEMIC AGENTS; E.G., 2-(6-(5-AMIDINO-1H-BENZIMIDAZOL-2-YL)-PYRID-3-YLCARBONYLAMINO)-3 -HYDROXYBUTYRIC ACID | AXYS PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | MAPT 2104/4885KDM4E 3525/4885CYP3A4 1190/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | MAPT 2289/4885KDM4E 1583/4885CYP3A4 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.